Ligne de temps

Nadira Frescaline
Post-doctorant(e)
22 févr. 2023
publication

Complete Genome Sequences of Bioluminescent Staphylococcus aureus Strains Xen31 and Xen36, Derived from Two Clinical Isolates.

Lire plus
09 sept. 2022
project

- NOVOPLASM – Un axe NOVateur pOur cicatriser les brûlures sévères infectées par l’application de PLASMa froid

Lire plus
01 janv. 2022
publication

Danger signals in traumatic hemorrhagic shock and new lines for clinical applications.

Lire plus
16 juin 2021
publication

Cold Atmospheric Plasma Promotes Killing of Staphylococcus aureus by Macrophages.

Lire plus
01 déc. 2020
publication

Physical plasma therapy accelerates wound re-epithelialisation and enhances extracellular matrix formation in cutaneous skin grafts.

Lire plus
28 août 2020
team

Groupe : Pathogenèse Bactérienne et Agents Antibactériens

Lire plus
08 août 2020
publication

A Murine Model of a Burn Wound Reconstructed with an Allogeneic Skin Graft.

Lire plus
01 nov. 2019
publication

Cold atmospheric plasma modulates endothelial nitric oxide synthase signalling and enhances burn wound neovascularisation.

Lire plus
01 janv. 2018
publication

Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.

Lire plus
01 déc. 2016
publication

Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.

Lire plus
01 déc. 2016
publication

Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.

Lire plus
05 juil. 2016
publication

OX40L blockade protects against inflammation-driven fibrosis.

Lire plus
21 mars 2015
publication

Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis.

Lire plus
01 janv. 2015
publication

Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.

Lire plus
01 nov. 2014
publication

The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.

Lire plus
01 févr. 2014
publication

Attenuation of flightless I improves wound healing and enhances angiogenesis in a murine model of type 1 diabetes.

Lire plus
01 oct. 2013
publication

Venous ulceration contaminated by multi-resistant organisms: larval therapy and debridement.

Lire plus
01 avr. 2013
publication

Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita.

Lire plus
01 janv. 2013
publication

The influence of Flightless I on Toll-like-receptor-mediated inflammation in a murine model of diabetic wound healing.

Lire plus
01 nov. 2012
publication

Lysosomal secretion of Flightless I upon injury has the potential to alter inflammation.

Lire plus
15 sept. 2012
publication

Flightless, secreted through a late endosome/lysosome pathway, binds LPS and dampens cytokine secretion.

Lire plus
12 sept. 2012
publication

Cytoskeletal protein Flightless (Flii) is elevated in chronic and acute human wounds and wound fluid: neutralizing its activity in chronic but not acute wound fluid improves cellular proliferation.

Lire plus
01 août 2009
publication

Attenuation of Flightless I, an actin-remodelling protein, improves burn injury repair via modulation of transforming growth factor (TGF)-beta1 and TGF-beta3.

Lire plus